Activity markers are used to determine whether deficiencies, overactivation or dysregulation in the complement system are causing, or contributing to, a person's disease or condition.
The Svar Complement activity markers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. The Svar assays for complement activity markers are developed to target the unique neoepitopes only presented at the complement component or complex when activated.
Just like the Svar Complement C4d, launched in 2018, the Complement TCC is a flexible and easy to use enzyme immunoassay with ready to use reagents and short incubation times leading to reduced hands-on-time for the user.
TCC is suitable for all situations where determination of complement activity is wanted. Increased TCC levels can be detected in both acute injury (trauma, sepsis, myocardial infarction) and in chronic inflammation diseases (SLE, RA, aHUS) and can be used successfully to rule out if a drug is toxic or if an adverse reaction is due to other related issues such as “infusion reactions”.
TCC is also well suited for studies of all medical devices in contact with blood, i.e. biological safety testing and part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.
TCC is also well suited for studies of all medical devices in contact with blood, i.e. biological safety testing and part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.
Benefits of Complement TCC:
For more information about our activity markers - TCC and C4d - please click here.
Activity markers are used to determine whether deficiencies, overactivation or dysregulation in the complement system are causing, or contributing to, a person's disease or condition.
The Svar Complement activity markers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. The Svar assays for complement activity markers are developed to target the unique neoepitopes only presented at the complement component or complex when activated.
Just like the Svar Complement C4d, launched in 2018, the Complement TCC is a flexible and easy to use enzyme immunoassay with ready to use reagents and short incubation times leading to reduced hands-on-time for the user.
TCC is suitable for all situations where determination of complement activity is wanted. Increased TCC levels can be detected in both acute injury (trauma, sepsis, myocardial infarction) and in chronic inflammation diseases (SLE, RA, aHUS) and can be used successfully to rule out if a drug is toxic or if an adverse reaction is due to other related issues such as “infusion reactions”.
TCC is also well suited for studies of all medical devices in contact with blood, i.e. biological safety testing and part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.
TCC is also well suited for studies of all medical devices in contact with blood, i.e. biological safety testing and part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.
Benefits of Complement TCC:
For more information about our activity markers - TCC and C4d - please click here.